Argus Downgrades Celgene (CELG) to Hold

Go back to Argus Downgrades Celgene (CELG) to Hold

UPDATE: Bernstein Upgrades Celgene (CELG) to Outperform

May 23, 2018 6:32 AM EDT

(Updated - May 23, 2018 8:09 AM EDT)

(updated to expand anlayst comment)

Bernstein upgraded Celgene (NASDAQ: CELG) from Market Perform to Outperform, price target $102.00 (from $121.00).

Analyst Arron Gal believes the worst case scenario relative to a generic Revlimid entry in April... More